Prognia
All Conditions
HepatologyICD-10: K74.6

Liver Cirrhosis: Current Treatment Guidelines & Management

Affects approximately 1.5% of the global adult population; 1 million deaths annually worldwide.

What is Liver Cirrhosis?

Liver cirrhosis is the final common pathway of chronic liver injury, characterised by extensive hepatic fibrosis and regenerative nodule formation that distort hepatic architecture and impair liver function. It is classified as compensated (no clinical complications) or decompensated (ascites, variceal haemorrhage, hepatic encephalopathy, hepatorenal syndrome, jaundice). Aetiology: alcohol (most common in Europe), MASLD/NASH (rapidly rising), viral hepatitis (HBV/HCV), autoimmune, cholestatic.

Pathophysiology

Repeated cycles of hepatocellular injury activate hepatic stellate cells (HSCs) via TGF-β signalling, driving collagen deposition and fibrogenesis. Portal hypertension develops as hepatic vascular resistance increases (structural component: fibrosis/nodules; dynamic component: increased hepatic vascular tone). Portal hypertension >10 mmHg (clinically significant portal hypertension, CSPH) drives complications: varices, ascites, portosystemic shunting. Bacterial translocation from the gut perpetuates systemic inflammation and infection complications.

Clinical Features & Symptoms

  • Compensated cirrhosis often asymptomatic
  • Fatigue, weakness, muscle wasting (sarcopenia)
  • Jaundice (scleral icterus, skin yellowing)
  • Ascites (abdominal distension, shifting dullness)
  • Peripheral oedema
  • Spider naevi, palmar erythema, leukonychia, Dupuytren's contracture
  • Hepatic encephalopathy (confusion, asterixis, altered consciousness)
  • Haematemesis or melaena (variceal bleeding)

Diagnosis

Clinical diagnosis supported by: liver function tests (low albumin, raised bilirubin, prolonged PT/INR), FBC (thrombocytopenia — portal hypertension), liver ultrasound (echogenic liver, splenomegaly, varices). FibroScan (transient elastography) >12.5 kPa highly specific for cirrhosis. Liver biopsy gold standard but not required when clinical evidence is sufficient. Score severity with Child-Pugh and MELD.

Current Treatment Guidelines

Treat underlying cause

Class I, Level A

Alcohol abstinence, antiviral therapy for HBV/HCV (cure possible with DAAs in HCV), weight loss/exercise for MASLD, immunosuppression for autoimmune hepatitis. Disease regression possible even at cirrhosis stage with complete viral suppression.

Primary variceal prophylaxis

Class I, Level A

Non-selective beta-blockers (propranolol, carvedilol) for medium/large varices. Carvedilol preferred (lower portal pressure reduction). Endoscopic variceal ligation (EVL) alternative if intolerant. Upper GI endoscopy at diagnosis to screen for varices.

Acute variceal haemorrhage

Class I, Level A

Terlipressin IV immediately. Blood transfusion target Hb 70–80 g/L. IV ceftriaxone 1 g/day (antibiotic prophylaxis for 7 days reduces mortality). Urgent endoscopy within 12 hours for EVL or injection sclerotherapy. TIPSS if refractory.

Ascites management

Class I, Level A

Moderate sodium restriction (<90 mmol/day). Spironolactone 100–400 mg/day ± furosemide. Large-volume paracentesis (LVP) for refractory ascites with IV albumin (8 g/L drained). TIPSS for refractory ascites.

SBP treatment and prophylaxis

Class I, Level A

Spontaneous bacterial peritonitis: IV cefotaxime 2 g TDS + IV albumin (1.5 g/kg at diagnosis, 1 g/kg at 72h) reduces hepatorenal syndrome risk. Long-term norfloxacin or ciprofloxacin prophylaxis after first SBP episode.

Hepatic encephalopathy

Class I, Level A

Identify and treat precipitating factors (infection, GI bleed, drugs, electrolyte disturbance). Lactulose titrated to 2–3 soft stools/day. Rifaximin 550 mg BD for secondary prevention (reduces hospitalisation by 50%).

Monitoring & Treatment Targets

Upper GI endoscopy every 1–3 years (varices surveillance). AFP and liver ultrasound every 6 months (HCC surveillance). Renal function, electrolytes, LFTs every 3–6 months. MELD score at each hepatology visit. Nutritional assessment; refer to dietitian.

Key Clinical Trials

RIFAXIMIN-α trialNEJM, 2010

Rifaximin 550 mg BD reduced overt hepatic encephalopathy episodes by 58% and hospitalisations by 50% vs placebo in patients with recurrent HE on lactulose

SORT trialNEJM, 2018

IV albumin for non-SBP cirrhosis complications (HRS, spontaneous bacteraemia, AKI) reduced 90-day hospital readmission and mortality vs standard care

External Resources

EASL Cirrhosis Guidelines 2018AASLD Cirrhosis Practice Guidance

AI Clinical Analysis

Requires free account

Ask Prognia AI about Liver Cirrhosis — get evidence-graded answers from PubMed, ESC, AHA, NICE, and ADA guidelines, and real clinical cases simultaneously.

Ask about Liver CirrhosisCreate Free Account

Frequently Asked Questions

What is the best score to assess cirrhosis severity?

Both Child-Pugh and MELD are used. MELD (INR, bilirubin, creatinine) is preferred for liver transplant prioritisation and short-term mortality prediction due to its objectivity. MELD-Na (adds serum sodium) is more accurate and now preferred by most transplant centres. Child-Pugh (A/B/C classification) is simpler and useful for surgical risk stratification and bedside staging.

How is spontaneous bacterial peritonitis (SBP) diagnosed and treated?

SBP is diagnosed by diagnostic paracentesis showing ascitic fluid PMN count ≥250 cells/mm³. Treatment: IV cefotaxime 2 g TDS for 5–7 days plus IV albumin (1.5 g/kg on day 1 and 1 g/kg on day 3) to prevent hepatorenal syndrome. Long-term norfloxacin 400 mg/day or ciprofloxacin is recommended as secondary prophylaxis after the first SBP episode.

Medical disclaimer: This content is intended for qualified healthcare professionals and does not constitute medical advice. Always apply clinical judgment and refer to current local guidelines and institutional protocols.